Literature DB >> 8987783

Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus.

T V Dunwiddie1, L Diao, H O Kim, J L Jiang, K A Jacobson.   

Abstract

The adenosine A3 receptor is expressed in brain, but the consequences of activation of this receptor on electrophysiological activity are unknown. We have characterized the actions of a selective adenosine A3 receptor agonist, 2-chloro-N6-(3-lodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA), and a selective A3 receptor antagonist, 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1, 4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS 1191), in brain slices from rat hippocampus. In the CA1 region, activation of A3 receptors had no direct effects on synaptically evoked excitatory responses, long-term potentiation, or synaptic facilitation. However, activation of A3 receptors with Cl-IB-MECA antagonized the adenosine A1 receptor-mediated inhibition of excitatory neurotransmission. The effects of Cl-IB-MECA were blocked by pretreatment with MRS 1191, which by itself had no effect on A1 receptor-mediated responses. The presynaptic inhibitory effects of baclofen and carbachol, mediated via GABA(B) and muscarinic receptors, respectively, were unaffected by Cl-IB-MECA. The maximal response to adenosine was unchanged, suggesting that the primary effect of Cl-IB-MECA was to reduce the affinity of adenosine for the receptor rather than to uncouple it. Similar effects could be demonstrated after brief superfusion with high concentrations of adenosine itself. Under normal conditions, endogenous adenosine in brain is unlikely to affect the sensitivity of A1 receptors via this mechanism. However, when brain concentrations of adenosine are elevated (e.g., during hypoxia, ischemia, or seizures), activation of A3 receptors and subsequent heterologous desensitization of A1 receptors could occur, which might limit the cerebroprotective effects of adenosine under these conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8987783      PMCID: PMC5470729     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  35 in total

Review 1.  Presynaptic inhibition in the hippocampus.

Authors:  S M Thompson; M Capogna; M Scanziani
Journal:  Trends Neurosci       Date:  1993-06       Impact factor: 13.837

2.  Cholinergic phosphatidylinositol modulation of inhibitory, G protein-linked neurotransmitter actions: electrophysiological studies in rat hippocampus.

Authors:  P F Worley; J M Baraban; M McCarren; S H Snyder; B E Alger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

3.  An A1-adenosine receptor, characterized by [3H] cyclohexyladenosine binding, mediates the depression of evoked potentials in a rat hippocampal slice preparation.

Authors:  M Reddington; K S Lee; P Schubert
Journal:  Neurosci Lett       Date:  1982-03-05       Impact factor: 3.046

4.  Adenosine A1 receptors inhibit adenylate cyclase activity and neurotransmitter release and hyperpolarize pyramidal neurons in rat hippocampus.

Authors:  T V Dunwiddie; B B Fredholm
Journal:  J Pharmacol Exp Ther       Date:  1989-04       Impact factor: 4.030

5.  Molecular cloning and characterization of the human A3 adenosine receptor.

Authors:  C A Salvatore; M A Jacobson; H E Taylor; J Linden; R G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

6.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Interactions in the behavioral effects of methylxanthines and adenosine derivatives.

Authors:  J J Katims; Z Annau; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

Review 8.  Adenosine and brain ischemia.

Authors:  K A Rudolphi; P Schubert; F E Parkinson; B B Fredholm
Journal:  Cerebrovasc Brain Metab Rev       Date:  1992

9.  4-Aminopyridine and low Ca2+ differentiate presynaptic inhibition mediated by neuropeptide Y, baclofen and 2-chloroadenosine in rat hippocampal CA1 in vitro.

Authors:  G J Klapstein; W F Colmers
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

10.  Adenosine receptors and behavioral actions of methylxanthines.

Authors:  S H Snyder; J J Katims; Z Annau; R F Bruns; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

View more
  44 in total

Review 1.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.

Authors:  Amanda Ford; Annie Castonguay; Martin Cottet; Joshua W Little; Zhoumou Chen; Ashley M Symons-Liguori; Timothy Doyle; Terrance M Egan; Todd W Vanderah; Yves De Koninck; Dilip K Tosh; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

3.  Adenosine A(1) receptor: Functional receptor-receptor interactions in the brain.

Authors:  Kathrin Sichardt; Karen Nieber
Journal:  Purinergic Signal       Date:  2007-09-05       Impact factor: 3.765

4.  A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro.

Authors:  Anna Maria Pugliese; Elisabetta Coppi; Giampiero Spalluto; Renato Corradetti; Felicita Pedata
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

5.  Internalization and desensitization of adenosine receptors.

Authors:  Elisabeth C Klaasse; Adriaan P Ijzerman; Willem J de Grip; Margot W Beukers
Journal:  Purinergic Signal       Date:  2007-11-13       Impact factor: 3.765

6.  Role of nitric oxide in the behavioral and neurochemical effects of IB-MECA in zebrafish.

Authors:  Caio Maximino; Julliany Gemaque; Rancés Benzecry; Monica Gomes Lima; Evander de Jesus Oliveira Batista; Domingos Wanderley Picanço-Diniz; Karen Renata Matos Oliveira; Anderson Manoel Herculano
Journal:  Psychopharmacology (Berl)       Date:  2014-11-13       Impact factor: 4.530

7.  Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors.

Authors:  Anna Maria Pugliese; Serena Latini; Renato Corradetti; Felicita Pedata
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

8.  Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.

Authors:  A H Li; S Moro; N Melman; X D Ji; K A Jacobson
Journal:  J Med Chem       Date:  1998-08-13       Impact factor: 7.446

9.  Tuning and fine-tuning of synapses with adenosine.

Authors:  A M Sebastião; J A Ribeiro
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Frequency facilitation at mossy fiber-CA3 synapses of freely behaving rats contributes to the induction of persistent LTD via an adenosine-A1 receptor-regulated mechanism.

Authors:  Hardy Hagena; Denise Manahan-Vaughan
Journal:  Cereb Cortex       Date:  2009-11-10       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.